Related Experiment Videos

Propranolol for infantile hemangiomas

Lorea Bagazgoitia1, Antonio Torrelo, Juan Carlos López Gutiérrez

  • 1Department of Dermatology, Hospital del Niño Jesús, Madrid, Spain.

Pediatric Dermatology
|March 10, 2011
PubMed

Insights

Oral propranolol is a rapid and effective treatment for infantile hemangiomas in children. This medication demonstrated consistent efficacy across various patient demographics and hemangioma types with minimal side effects.

Area of Science:

  • Pediatric Dermatology
  • Pharmacology
  • Vascular Anomalies

Background:

  • Infantile hemangiomas (IH) are common benign vascular tumors in infants.
  • Limited treatment options exist, with propranolol emerging as a promising therapy.
  • Multicenter studies are crucial to validate propranolol's efficacy and safety in IH.

Purpose of the Study:

  • To evaluate the efficacy and adverse effects of oral propranolol in treating infantile hemangiomas.
  • To assess the treatment response across different patient and hemangioma characteristics.
  • To determine the optimal dosage and duration for propranolol therapy in IH.

Main Methods:

  • Retrospective analysis of 71 infants treated with oral propranolol (1 mg/kg every 12 hours) for at least 12 weeks.
  • Photographic assessment of hemangioma severity using a standardized 10-point scale by five independent observers.
  • Statistical analysis to determine treatment efficacy at various time points and across subgroups.

Main Results:

  • Propranolol showed rapid and significant efficacy in reducing infantile hemangioma severity by 4 weeks (p < 0.001), with continued improvement up to 32 weeks.
  • Treatment response was consistent regardless of infant's sex, age, hemangioma type (segmental/nonsegmental), location, ulceration, or depth.
  • Adverse effects were minimal, with agitated sleep reported in only 10 of 71 patients.

Conclusions:

  • Oral propranolol (2 mg/kg/day) is a well-tolerated and effective treatment for infantile hemangiomas.
  • The drug's efficacy is not influenced by various clinical factors, suggesting broad applicability.
  • Further prospective studies are warranted to establish the definitive role of propranolol in infantile hemangioma management.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...